About KINTOR PHARMA-B Company

We are a clinical development innovative drug company in China that focuses on developing potential first-of-it/best-in-class drugs. We have 6 potentially first-in-class/best-in-class drugs under development in phase I-III clinical stages, and are committed to becoming a leading enterprise in the research, development and commercialization of innovative therapies. Our products are dedicated to solving disease areas that do not meet clinical needs, and the pipeline mainly covers dermatological (such as hair loss, acne, etc.) and oncology indications. KX-826 KX-826 is an AR antagonist. We are currently developing KX-826 as a potential first-of-its-kind topical treatment for androgenic alopecia (AGA) and acne. AR-PROTAC compound (GT20029) GT20029 is a topical AR-PROTAC compound developed using the PROTAC platform independently developed by the Group. We are currently developing GT20029 to treat hair loss and acne. proclamide (GT0918) Puclamide (GT0918) is a second-generation AR antagonist with the potential to become the best-in-class drug. We are currently developing proclamide to treat mCRPC, COVID-19, and AR+ metastatic breast cancer. GT1708F (hedgehog/SMO inhibitor) GT1708F (hedgehog/SMO inhibitor) is a hedgehog signaling pathway inhibitor. We are currently developing GT1708F mainly for the treatment of idiopathic pulmonary fibrosis (IPF) and hematologic tumors. GT0486 GT0486 is a PI3K/mTOR signaling pathway inhibitor and is a second-generation mTOR inhibitor. We are currently developing GT0486, which is mainly used to treat metastatic solid tumors such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC). ALK-1 antibody (GT90001) The ALK-1 antibody is a new anti-angiogenesis inhibitor that we obtained an exclusive global license from Pfizer in 2018, and targets ALK-1, a new global biological target. We are developing ALK-1 antibodies to treat metastatic HCC and various solid tumors.